Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial

Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma

(2020) Haijing Deng et al.   Liver Cancer

The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas

(2020) Manling Huang et al.   CLINICAL CANCER RESEARCH

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

(2020) Michael S Lee et al.   LANCET ONCOLOGY

Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial

(2020) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

(2020) Harry Ho Man Ng et al.   Journal for ImmunoTherapy of Cancer

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy

(2019) Anthony Tanoto Tan et al.   GASTROENTEROLOGY

Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC

(2019) Kohei Shigeta et al.   HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

(2018) Mayuko Furuta et al.   Oncotarget

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

(2018) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Epidemiology and Management of Hepatocellular Carcinoma

(2018) Laura Kulik et al.   GASTROENTEROLOGY

Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma

(2016) Yung-Tuen Chiu et al.   JOURNAL OF HEPATOLOGY

Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma

(2015) Joon Hyeok Lee et al.   GASTROENTEROLOGY

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient

(2015) Waseem Qasim et al.   JOURNAL OF HEPATOLOGY

The global burden of liver disease: The major impact of China

(2014) Fu-Sheng Wang et al.   HEPATOLOGY

Acute hepatitis B infection associated with drug-resistant hepatitis B virus

(2010) Zhihui Xu et al.   JOURNAL OF CLINICAL VIROLOGY

Safety analysis ofex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study

(2009) Lisbeth Barkholt et al.   Immunotherapy

Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients

(2009) Zheng Zhang et al.   JOURNAL OF HEPATOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE